Aktis OncologyAKTS -1.90%9 9-Day RSI is 52.45 as of Jul. 12, 2026. GuruFocus rates AKTS with a GF Score™ of 9/100. The stock has 1 warning sign investors should review. Among 1,422 Biotechnology companies, Aktis Oncology ranks worse than 57.38% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-12), Aktis Oncology's 9-Day RSI is 52.45.
The industry rank for Aktis Oncology's 9-Day RSI or its related term are showing as below:
AKTS's 9-Day RSI is ranked worse than 57.38% of 1422
companies
in the Biotechnology industry
Industry Median: 50.12
vs AKTS: 52.45
Aktis Oncology (NAS:AKTS) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Aktis Oncology 9-Day RSI Related Terms
AKTS vs ZBIO, MLTX, AVBP: 9-Day RSI Comparison
For the Biotechnology subindustry, Aktis Oncology's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aktis Oncology 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aktis Oncology's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Aktis Oncology's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aktis Oncology (AKTS) has a 9-Day RSI of 52.45 as of Jul. 12, 2026. According to the industry distribution chart, Aktis Oncology ranks #816 out of 1422 companies in the Biotechnology industry, placing it in the top 57.4%.
Is Aktis Oncology's 9-Day RSI too high?
Aktis Oncology's current 9-Day RSI is 52.45. The Biotechnology industry median 9-Day RSI is 50.12. Aktis Oncology's value of 52.45 is 4.6% above this industry median. Based on the distribution chart, Aktis Oncology ranks #816 out of 1422 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's 9-Day RSI compare to ZBIO and MLTX?
According to the Biotechnology industry distribution chart, Aktis Oncology ranks #816 out of 1422 companies for 9-Day RSI. This places Aktis Oncology in the lower half of its industry. The industry median 9-Day RSI is 50.12. Aktis Oncology's value of 52.45 is 4.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 50.12, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aktis Oncology's current 9-Day RSI of 52.45 is 4.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 50.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aktis Oncology's current 9-Day RSI is 52.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current 9-Day RSI of 52.45. The current 9-Day RSI is 52.45 and 4.6% above the Biotechnology industry median of 50.12. Aktis Oncology's overall GF Score™ is 9/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current 9-Day RSI is 52.45 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score
Get the complete analysis for AKTS
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AKTS has been successfully added to your 